甘氨双唑钠注射剂联合同期放化疗治疗
原发性晚期宫颈癌的临床研究

doi:10.3760/cma.j.issn.1673-422X.2018.12.005

摘要/Abstract

摘要： 目的观察甘氨双唑钠注射剂联合同期放化疗治疗原发性晚期宫颈癌的临床疗效及安全性。方法选择2010年11月至2016年11月青海省人民医院收治的84例原发性晚期宫颈癌患者，按随机数字表法分为对照组（42例）和试验组（42例）。对照组予以常规放化疗，试验组基于对照组加以甘氨双唑钠治疗。比较两组患者的临床疗效，血清肿瘤标志物如鳞状细胞癌相关抗原（SCC）、组织多肽特异性抗原（TPS）、可溶性人类组织相容性复合物Ⅰ类分子链相关基因A蛋白（sMICA）、缺氧诱导因子1α（HIF1α）和人表皮生长因子受体2（Her2）水平，以及不良反应的发生情况。结果治疗后4个月，试验组和对照组的总有效率分别为73.81%（31/42）和50.00%（21/42），试验组总有效率优于对照组，差异有统计学意义（χ2=5.048，P=0.025）。治疗后4个月，试验组SCC［（2.67±0.76）ng/ml∶（4.10±0.94）ng/ml］、TPS［（56.85±6.39）U/L∶（86.69±12.62）U/L］、sMICA［（90.31±11.25）ng/L∶（129.46±16.60）ng/L］、HIF1α［（55.47±7.04）ng/L∶（68.07±7.97）ng/L］和Her2［（44.64±4.96）U/L∶（53.07±6.56）U/L］均低于对照组，差异均有统计学意义（t=7.667，P<0.001；t=13.671，P<0.001；t=12.653，P<0.001；t=7.679，P<0.001；t=6.643，P<0.001）。试验组和对照组的骨髓抑制发生率分别为23.81%(10/42)、21.43%(9/42)，胃肠道反应发生率分别为19.05%(8/42)、14.29%(6/42)，心电图异常发生率分别为4.76%(2/42)、2.38%(1/42)，总不良反应发生率分别为47.62%（20/42）和38.10%（16/42），两组总不良反应发生率差异无统计学意义（χ2=0.778，P=0.378）。结论甘氨双唑钠注射剂联合同期放化疗治疗原发性晚期宫颈癌的临床疗效确切，其能够显著降低SCC、TPS、sMICA、HIF1α及Her2水平，且不增加不良反应的发生率。

关键词: 宫颈肿瘤, 甘氨双唑钠, 同期放化疗, 疗效, 安全性

Abstract: ObjectiveTo observe the clinical efficacy and safety of sodium glycididazole injection combined with concurrent chemoradiotherapy in treatment of primary advanced cervical cancer. MethodsA total of 84 patients with primary advanced cervical cancer were selected from November 2010 to November 2016 in Qinghai Provincial People′s Hospital. All the patients were divided into the control group (n=42) and the experimental group (n=42) according to random number table method. The control group was treated with routine chemoradiotherapy, and the experimental group was treated with sodium glycididazole injection based on the control group. The curative effects, levels of serum tumor markers such as squamous cell carcinoma associated antigen (SCC), tissue polypeptide specific antigen (TPS), soluble human major histocompatibility complexⅠ molecular chain related gene A protein (sMICA), hypoxia inducible factor1α (HIF1α), human epidermal growth factor receptor 2 (Her2) and adverse reactions of the two groups were compared. ResultsFour months after treatment, the total effective rates of the experimental group and the control group were 73.81% (31/42) and 50.00%(21/42). The total effective rate in the experimental group was higher than that in the control group, and the difference was statistically significant (χ2=5.048, P=0.025). Four months after treatment, the levels of SCC ［(2.67±0.76 ) ng/ml vs. (4.10±0.94) ng/ml］, TPS ［(56.85±6.39) U/L vs. (86.69±12.62) U/L］, sMICA ［(90.31±11.25) ng/L vs. (129.46±16.60) ng/L］, HIF1α ［(55.47±7.04) ng/L vs. (68.07±7.97) ng/L］ and Her2 ［(44.64±4.96) U/L vs. (53.07±6.56) U/L］ in the experimental group were lower than those in the control group, with statistically significant differences (t=7.667, P<0.001; t=13.671, P<0.001; t=12.653, P<0.001; t=7.679, P<0.001; t=6.643, P<0.001). The occurrence rates of bone marrow suppression of the experimental group and the control group were 23.81% (10/42) and 21.43% (9/42), the occurrence rates of gastrointestinal reaction were 19.05% (8/42) and 14.29% (6/42), the occurrence rates of abnormal electrocardiogram were 4.76% (2/42) and 2.38% (1/42), and the tatal adverse reaction rates were 47.62% (20/42) and 38.10% (16/42). The difference of the total adverse reaction rates between the experimental group and the control group was not statistically significant (χ2=0.778, P=0.378). ConclusionThe clinical efficacy of sodium glycididazole injection combined with concurrent chemoradiotherapy is definite for primary advanced cervical cancer. This treatment regimen can reduce serum levels of SCC, TPS, sMICA, HIF1α and Her2, and not increase the incidence of adverse reactions.

Key words: Uterine cervical neoplasms, Sodium glycididazole, Concurrent chemoradiotherapy, Curative effect, Security

魏民,徐凌燕,韩婕,王鹏. 甘氨双唑钠注射剂联合同期放化疗治疗原发性晚期宫颈癌的临床研究[J]. 国际肿瘤学杂志, 2018, 45(12): 727-730.

Wei Min, Xu Lingyan, Han Jie, Wang Peng. Clinical research of sodium glycididazole injection combined with concurrent chemoradiotherapy in treatment of primary advanced cervical cancer[J]. Journal of International Oncology, 2018, 45(12): 727-730.

参考文献

［1］ Aldelaijan S, Wadi-Ramahi S, Nobah A, et al. Commissioning of applicator-guided stereotactic body radiation therapy boost with high-dose-rate brachytherapy for advanced cervical cancer using radiochromic film dosimetry［J］. Brachytherapy, 2017, 16(4): 893-902. DOI: 10.1016/j.brachy.2017.03.009. ［2］ van Heerden LE, Houweling AC, Koedooder K, et al. Structure-based deformable image registration: added value for dose accumulation of external beam radiotherapy and brachytherapy in cervical cancer［J］. Radiother Oncol, 2017, 123 (2): 319-324. DOI: 10.1016/j.radonc.2017.03.015. ［3］ Zeng YC, Wu R, Xing R, et al. Radiation-enhancing effect of sodium glycididazole in patients suffering from non-small cell lung cancer with multiple brain metastases: a randomized, placebo-controlled study［J］. Cancer Radiother, 2016, 20(3): 187-192. DOI: 10.1016/j.canrad.2016.02.008. ［4］ Vattai A, Cavailles V, Sixou S, et al. Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer［J］. Oncotarget, 2017, 8(62): 105356-105371. DOI: 10.18632/oncotarget.22187. ［5］中华人民共和国国家卫生和计划生育委员会. 宫颈癌及癌前病变规范化诊疗指南（试行）［J］. 慢性病学杂志, 2013, 14(6): 401-410. ［6］ Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026. ［7］ Tantitamit T, Termrungruanglert W, Khemapech N, et al. A model approach for assessing the benefits of HPV testing against cytology in screening for cervical cancer precursors in Thailand［J］. Asian Pac J Cancer Prev, 2017, 18(5): 1271-1275. DOI: 10.22034/APJCP.2017.18.5.1271. ［8］李铭仪, 刘锦全, 张秀萍, 等. 甘氨双唑钠联合PLF方案同期放化疗治疗局部晚期鼻咽癌的临床对照研究［J］. 广东医学, 2013, 34(1): 132-136. DOI: 10.3969/j.issn.1001-9448.2013.01.056. ［9］惠慧, 吴磊, 付玉兰, 等. 同步放化疗联合甘氨双唑钠治疗中晚期宫颈癌的临床研究［J］. 现代肿瘤医学, 2016, 24(9): 1438-1440. DOI: 10.3969/j.issn.1672-4992.2016.09.030. ［10］ Zhi W, Ferris D, Sharma A, et al. Twelve serum proteins progressively increase with disease stage in squamous cell cervical cancer patients［J］. Int J Gynecol Cancer, 2014, 24(6): 1085-1092. DOI: 10.1097/IGC.0000000000000153.

[1]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[2]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[3]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[4]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[5]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[6]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[7]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[8]	史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[9]	陆佳玲, 黄慧娟, 刘丹, 陈妍心, 马骁, 吴德沛. 博纳吐单抗治疗急性B淋巴细胞白血病的疗效和安全性[J]. 国际肿瘤学杂志, 2022, 49(8): 494-498.
[10]	褚雪镭, 毛昀, 薛鹏, 李林潞, 陈美池, 袁淳晟, 秦晓艳, 朱世杰. 化疗剂量强度对晚期结肠癌患者近期疗效的影响：基于真实世界数据研究[J]. 国际肿瘤学杂志, 2022, 49(7): 408-415.
[11]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[12]	张慎锋, 刘杰, 祝情情, 阚士峰, 孙晋军, 王涛, 邱梅清. 长春瑞滨节拍化疗治疗一线失败后驱动基因阴性晚期老年非小细胞肺癌的疗效和安全性[J]. 国际肿瘤学杂志, 2022, 49(7): 441-443.
[13]	熊婵, 阎英, 谢晓冬, 孟繁杰, 于卉影. 辐射诱导的多倍体宫颈癌HeLa细胞生物学特性研究[J]. 国际肿瘤学杂志, 2022, 49(5): 263-269.
[14]	肖梦霞, 姚颐, 高利昆, 宋启斌. 组织TSR值对NSCLC免疫治疗疗效的预测价值[J]. 国际肿瘤学杂志, 2022, 49(5): 270-275.
[15]	高珊, 陆敏秋, 石磊, 褚彬, 房立娟, 项秋晴, 王宇彤, 丁月华, 鲍立. 伊沙佐米联合方案治疗复发/难治多发性骨髓瘤的疗效和安全性分析[J]. 国际肿瘤学杂志, 2022, 49(5): 286-291.